Table 3.
Efficacy Results
| Tumor | OR, No. (%) | CR, No. (%) | PR, No. (%) | SD, No. (%) | Median PFS, Weeks (95% CI) |
|---|---|---|---|---|---|
| B-cell lymphoma (n = 31) | 8 (26) | 3 (10) | 5 (16) | 16 (52) | 23 (7 to 44) |
| DLBCL (n = 11) | 4 (36) | 2 (18) | 2 (18) | 3 (27) | 7 (6 to 29) |
| FL (n = 10) | 4 (40) | 1 (10) | 3 (30) | 6 (60) | NR (7 to NR) |
| Other B-cell lymphoma (n = 10) | 0 | 0 | 0 | 7 (70) | 11 (3 to 39) |
| T-cell lymphoma (n = 23) | 4 (17) | 0 | 4 (17) | 10 (43) | 10 (7 to 33) |
| MF (n = 13) | 2 (15) | 0 | 2 (15) | 9 (69) | 10 (7 to 35) |
| PTCL (n = 5) | 2 (40) | 0 | 2 (40) | 0 | 14 (3 to NR) |
| Other CTCL (n = 3) | 0 | 0 | 0 | 0 | 7 (6 to NR) |
| Other non-CTCL (n = 2) | 0 | 0 | 0 | 1 (50) | 10 (2 to 18) |
| Multiple myeloma (n = 27) | 1 (4) | 1 (4)* | 0 | 17 (63) | 10 (5 to 15) |
Abbreviations: CR, complete response; CTCL, cutaneous T-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MF, mycosis fungoides; NR, not reported; OR, objective response; PFS, progression-free survival; PR, partial response; PTCL, peripheral T-cell lymphoma; SD, stable disease.
*
CR was obtained after radiotherapy. SD was the best response to nivolumab.